NYSE:BDX
BECTON DICKINSON & CO
A global medical technology powerhouse providing essential diagnostic, surgical, and life science tools to healthcare providers worldwide.
Key Metrics
Investment Thesis
Bull Case
BDX offers a stable defensive profile within the healthcare sector, supported by a diversified revenue stream that mitigates single-product risks. The company's consistent ability to generate strong free cash flow enables ongoing shareholder returns and strategic investments in R&D without relying on external debt financing. As an essential provider of life-saving medical equipment, BDX benefits from secular tailwinds such as aging demographics and increasing global healthcare spending.
Bear Case
The stock faces headwinds from a maturing market where total addressable revenue growth is limited outside of M&A activity. High levels of debt issuance and significant cash outflows for financing activities suggest the company may be using leverage to fund operations or strategic initiatives that dilute equity value over time. Intense competition in the medical device space could pressure pricing power, potentially leading to margin compression if volume growth fails to compensate.
About BECTON DICKINSON & CO
Becton, Dickinson and Company (BDX) is a global leader in medical technology, life science tools, and laboratory diagnostics serving healthcare professionals and institutions worldwide. The company specializes in critical care, surgery, infusion therapy, and infection prevention through its diverse portfolio of innovative products. BDX operates across North America, Europe, and the Asia-Pacific regions, delivering essential solutions that improve patient outcomes and streamline clinical workflows.
Analysis
Management Discussion
Despite a slight dip in net income from $1.71B in 2024 to $1.68B in 2025, the company successfully grew revenue to $21.84B, demonstrating resilience and pricing power in a mature market. Strong operating cash flow of $3.43B highlights the quality of earnings, allowing for significant capital return via dividends and share repurchases while maintaining a robust balance sheet with over $641M in cash.
Industry Overview
The global medical technology industry is characterized by high barriers to entry due to stringent regulatory requirements and the need for extensive clinical validation of new products. Growth drivers include technological advancements in minimally invasive surgery, personalized medicine diagnostics, and the expanding healthcare infrastructure in emerging markets. Consolidation remains a key trend as smaller players seek scale and larger companies acquire niche technologies to expand their portfolios.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $19.37B | $20.18B | $21.84B |
| Cost of Revenue | $11.20B | $11.05B | $11.91B |
| Gross Profit | $8.17B | $9.12B | $9.93B |
| Operating Expenses | $6.06B | $6.73B | $7.35B |
| Operating Income | $2.11B | $2.40B | $2.58B |
| R&D | $1.24B | $1.19B | $1.26B |
| G&A | $4.72B | $4.86B | $5.28B |
| Stock-Based Comp | $259.0M | $247.0M | $258.0M |
| D&A | $2.29B | $2.29B | $2.46B |
| Depreciation | $696.0M | $676.0M | $728.0M |
| Amortization | $1.47B | $1.47B | $1.59B |
| Other OpEx | $103.0M | $681.0M | $803.0M |
| Non-Operating Income | $-449.0M | $-392.0M | $-698.0M |
| Interest Expense | $452.0M | $528.0M | $613.0M |
| Interest Income | $49.0M | $163.0M | $38.0M |
| Pre-Tax Income | $1.66B | $2.00B | $1.88B |
| Income Tax | $132.0M | $300.0M | $203.0M |
| Continuing Ops | $1.53B | $1.71B | $1.68B |
| Discontinued Ops | $-46.0M | $0 | $0 |
| Net Income | $1.48B | $1.71B | $1.68B |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $1.48B | $1.71B | $1.68B |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $8.68B | $10.47B | $9.26B |
| Cash & Equivalents | $1.42B | $1.72B | $641.0M |
| Accounts Receivable | $2.53B | $3.03B | $2.99B |
| Inventory | $3.27B | $3.84B | $3.89B |
| Other Current Assets | $1.45B | $1.88B | $1.73B |
| Long-Term Assets | $44.10B | $46.82B | $46.07B |
| PP&E (Net) | $6.56B | $6.82B | $7.00B |
| Goodwill | $24.52B | $26.46B | $26.61B |
| Operating Leases | $517.0M | $876.0M | $885.0M |
| Other LT Assets | $12.51B | $12.66B | $11.58B |
| Total Assets | $52.78B | $57.29B | $55.33B |
| Current Liabilities | $6.64B | $8.96B | $8.31B |
| Accounts Payable | $1.64B | $1.90B | $1.97B |
| Current Leases | $117.0M | $142.0M | $135.0M |
| Taxes Payable | $139.0M | $168.0M | $329.0M |
| Other Current Liab | $2.14B | $3.27B | $2.77B |
| Long-Term Liabilities | $20.34B | $22.44B | $21.62B |
| Long-Term Debt | $14.74B | $17.94B | $17.62B |
| LT Operating Leases | $414.0M | $667.0M | $704.0M |
| Other LT Liab | $5.19B | $3.83B | $3.30B |
| Total Liabilities | $26.98B | $31.40B | $29.93B |
| Shareholders' Equity | $25.80B | $25.89B | $25.39B |
| Retained Earnings | $15.54B | $16.14B | $16.62B |
| AOCI | $-1.55B | $-1.73B | $-1.90B |
| Treasury Stock | $8.30B | $8.81B | $9.81B |
| Total L&E | $52.78B | $57.29B | $55.33B |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $1.48B | $1.71B | $1.68B |
| Non-Cash Adjustments | $1.53B | $691.0M | $1.51B |
| Working Capital Changes | $-27.0M | $1.40B | $244.0M |
| Cash from Operations | $2.99B | $3.80B | $3.43B |
| Capital Expenditures | $874.0M | $725.0M | $760.0M |
| Cash from Investing | $-716.0M | $-5.51B | $-818.0M |
| Debt Issuances | $1.66B | $4.52B | $0 |
| Debt Repayments | $2.15B | $1.14B | $1.79B |
| Share Buybacks | $0 | $500.0M | $1.00B |
| Dividends Paid | $1.11B | $1.10B | $1.20B |
| Cash from Financing | $-1.96B | $2.09B | $-3.62B |
| FX Effect | $5.0M | $4.0M | $0 |
| Net Change in Cash | $322.0M | $375.0M | $-1.00B |
| Beginning Cash | $1.16B | $1.48B | $1.86B |
| Ending Cash | $1.48B | $1.86B | $851.0M |
Frequently Asked Questions
How does BECTON DICKINSON & CO make money?
The company's revenue is driven by four primary segments: Medical Technologies (infusion therapy, catheters, and monitoring), Laboratory Diagnostics (testing platforms and reagents for clinical labs), Life Science Tools (equipment and consumables for R&D), and Critical Care & Surgery (anesthesia machines, surgical instruments, and disposable supplies).
What are the main risks for BDX?
Rapid technological disruption from emerging competitors could erode BDX's installed base if it fails to innovate quickly enough. Regulatory changes in pricing and reimbursement policies across different markets pose ongoing pressure on margins and sales growth. The high cost of raw materials and supply chain disruptions could impact the gross margin structure of its consumable-heavy business model.
What is BDX's competitive advantage?
BDX possesses a massive installed base of its proprietary equipment in hospitals, creating high switching costs for customers and ensuring recurring revenue from consumable sales. The company maintains extensive regulatory approvals and intellectual property portfolios that protect its market share in specialized areas like anesthesia and infusion management. Its global distribution network and deep relationships with key opinion leaders in clinical settings provide a significant barrier to entry for competitors.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.